NCT06660862 2026-01-08Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.University of ChicagoPhase 4 Not yet recruiting80 enrolled